Physician profile
Ashish Ojha
NPI 1013905645
$1,776.64
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $260 · 2021: $889 · 2022: $149 · 2024: $15.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $380.88 | 2019-2022 | |
| Abbvie INC. | $370.33 | 2021-2022 | |
| Novo Nordisk INC | $225.09 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $130.61 | 2019-2021 | |
| Amarin Pharma, INC. | $110.59 | 2019-2021 | |
| Amgen INC. | $101.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.84 | 2019-2020 | |
| Esperion Therapeutics, INC. | $56.06 | 2021 | |
| Astellas Pharma US INC | $54.92 | 2019-2022 | |
| Abbott Laboratories | $50.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.07 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.19 | 2019 | |
| Lilly USA, LLC | $24.24 | 2021 | |
| Glaxosmithkline, LLC. | $22.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.07 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $16.30 | 2019 | |
| Vistapharm, INC. | $15.38 | 2021 | |
| Genentech USA, INC. | $15.00 | 2019 | |
| Phadia US INC. | $13.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Ojha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.